Poseida Therapeutics/PSTX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Poseida Therapeutics

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. Its pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors, as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. Its approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, Booster Molecule and nanoparticle and hybrid gene delivery technologies, as well as in-house GMP cell therapy manufacturing. Its lead programs, including P-FVIII-101, a non-viral approach. Its product candidate P-BCMA-ALLO1 and P-BCMACD19-ALLO1 is developed for patients with multiple myeloma. P-BCMA-ALLO1 is in a Phase I trial, being developed for patients with relapsed/refractory multiple myeloma.

Ticker

PSTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Mark Gergen

Employees

335

Headquarters

San diego, United States

PSTX Metrics

BasicAdvanced
$290M
Market cap
-
P/E ratio
-$1.18
EPS
0.53
Beta
-
Dividend rate
$290M
0.53121
$4.27
$1.54
685K
2.557
69.38
69.38
-12.88%
-37.78%
-89.91%
-49.17%
3.514
3.421
3.668
-40.82%
-94.86%

What the Analysts think about PSTX

Analyst Ratings

Majority rating from 5 analysts.
Buy

PSTX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-86.12% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$28M
12.85%
Net income
-$24M
-4.35%
Profit margin
-86.12%
-15.24%

PSTX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 40.48%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.32
-$0.35
-$0.27
-$0.25
-
Expected
-$0.53
-$0.29
-$0.39
-$0.42
-$0.41
Surprise
-39.39%
19.66%
-30.05%
-40.48%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Poseida Therapeutics stock?

Poseida Therapeutics (PSTX) has a market cap of $290M as of June 20, 2024.

What is the P/E ratio for Poseida Therapeutics stock?

The price to earnings (P/E) ratio for Poseida Therapeutics (PSTX) stock is 0 as of June 20, 2024.

Does Poseida Therapeutics stock pay dividends?

No, Poseida Therapeutics (PSTX) stock does not pay dividends to its shareholders as of June 20, 2024.

When is the next Poseida Therapeutics dividend payment date?

Poseida Therapeutics (PSTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Poseida Therapeutics?

Poseida Therapeutics (PSTX) has a beta rating of 0.53. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Poseida Therapeutics stock price target?

The target price for Poseida Therapeutics (PSTX) stock is $14, which is NaN% below the current price of $. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Poseida Therapeutics stock

Buy or sell Poseida Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing